3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Small Cell Lung Carcinoma
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Lymphoma, Large B-Cell, Diffuse
11
Lung Neoplasms
10
Burkitt Lymphoma
9
Leukemia, Myeloid, Acute
8
Lymphoma
7
Hodgkin Disease
6
Carcinoma, Non-Small-Cell Lung
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms
5
Multiple Myeloma
5
Lymphoma, Non-Hodgkin
5
Lymphoma, B-Cell
5
Sarcoma, Ewing
3
Sarcoma
3
Rhabdomyosarcoma
3
Rhabdoid Tumor
3
Retinoblastoma
3
Recurrence
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neuroblastoma
3
Neoplasms, Germ Cell and Embryonal
3
Myelodysplastic Syndromes
3
Medulloblastoma
3
Lymphoma, Mantle-Cell
3
Lymphoma, Follicular
3
Leukemia
3
Immunoblastic Lymphadenopathy
3
Seminoma
2
Interventions
X-Rays
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Biopsy
4
ulixertinib
2
tipifarnib
2
selpercatinib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
Cyclophosphamide
2
tazemetostat
1
palbociclib
1
olaparib
1
fludarabine phosphate
1
fludarabine
1
etoposide phosphate
1
Vemurafenib
1
Thiotepa
1
Tacrolimus
1
Sirolimus
1
Pharmacogenomic Variants
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Melphalan
1
Lenalidomide
1
LY3023414
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Histiocytosis, Langerhans-Cell
×
Etoposide
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled